
26 October 2023
3B Future Health Gp S.A.R.L. The first investors’ meeting hosted by 3B Future Health Fund II
18 April 2023
NeoPhore signs research collaboration with The Institute of Cancer Research
14 April 2023
Geneos Therapeutics Secures $5 Million in Series A3 Financing
19 January 2023
NeoPhore completes extension to Series B financing to further advance discovery pipeline
20 December 2022
iOnctura awarded EUR17.5 million funding from the EIC Accelerator for clinical development of novel pancreatic cancer therapy
17 November 2022
AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failurewith AC01 in the EU and UK

19 October 2022
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solidtumors

11 October 2022
Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform
22 September 2022
Roca Therapeutics completes seed funding round
8 September 2022
AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure
28 June 2022
Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology
11 May 2022
On Target Laboratories, Inc. Announces Presentation of the Results from the ELUCIDATE Phase 3 Trial for CYTALUX™ (pafolacianine) injection for Intraoperative Molecular Imaging of Lung Cancer
10 May 2022
Domain Therapeutics raises $42m Series A financing
16 March 2022
Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
2 March 2022
Epsilogen Announces Completion of Oversubscribed 30.75 Million ($41.20 Million) Series B Financing
21 February 2022
Labcorp Completes Acquisition of Personal Genome Diagnostics
27 January 2022
3B Future Health promotes Marianne Bjørdal to Partner
29 November 2021
FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions
23 November 2021
FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor
23 November 2021
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
2 November 2021
OncoResponse Announces Initiation of Phase 1 Trial of OR2805 – Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy – in Patients with Advanced Cancer
26 October 2021
GenEp Raises $1.45 Million Seed Financing
6 October 2021
OncoResponse Announces Presentations at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021)
26 August 2021
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
10 August 2021
Tesis Labs and Personal Genome Diagnostics Announce Collaboration to Advance Cancer Profiling and Treatment
3 August 2021
Personal Genome Diagnostics Appoints Jamie Platt, Ph.D., as Chief Operations Officer
27 July 2021
iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-funded by Innosuisse
20 July 2021
iOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin Inhibitor IOA-289
7 July 2021
ONCORESPONSE APPOINTS SEAN McCARTHY TO BOARD OF DIRECTORS
15 June 2021
Personal Genome Diagnostics Enters Collaborative Partnership with Clinical Molecular Diagnostics Laboratory of Major University Health System
15 June 2021
UTILITY Therapeutics Preparing NDA Submission
10 June 2021
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
19 May 2021
Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments
17 May 2021
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
11 May 2021
OncoResponse Appoints Chris Russell as Chief Financial Officer
11 May 2021
UTILITY Therapeutics Announces Scientific Advisory Board
10 May 2021
Fore Biotherapeutics Opens U.S. Headquarters in Philadelphia Biotech Hub
3 May 2021
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
13 April 2021
Start-up GreenBone closes a EUR10m Series B round
31 March 2021
OncoResponse Raises $40.6 Million Series C Financing
24 March 2021
3B FUTURE HEALTH GP S.A.R.L. ANNOUNCES THE LAUNCH OF 3B FUTURE HEALTH FUND II
18 March 2021
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
9 March 2021
NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline
24 February 2021
NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board
4 February 2021
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
21 September 2020
Novellus Closes $57M Series C Financing
10 September 2020
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
21 July 2020
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
14 July 2020
3B Future Health Fund Announces New Investment in iOnctura
8 June 2020
QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test
14 April 2020
OncoResponse Appoints Robert Lechleider, MD as Chief Medical Officer; Promotes Kamal Puri, PhD to Chief Scientific Officer
31 January 2020
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
30 January 2020
The GreenBone bone substitute achieves CE certification
15 July 2019
Helsinn Investment Fund Announces First Exit
19 March 2019
Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced
19 February 2019
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
23 January 2019
QuantuMDx & St George’s begin field study: cervical cancer screening test
30 April 2018
NovellusDx Announces It Has Completed an Equity Financing of $6 Million
28 March 2018
Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced
14 March 2018
On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn
30 January 2018
Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement
5 September 2017
AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round
16 June 2017
Helsinn Investment Fund Leads the Financial Round in GreenBone
8 May 2017
Helsinn Investment Fund Invests in Aadi Bioscience
10 October 2016
Helsinn Group Introduces Helsinn Investment Fund
10 October 2016
Helsinn Investment Fund Invests £2.0 Million in QuantuMDx
10 October 2016
Helsinn Investment Fund to Invest $3.5 Million in OncoResponse
8 August 2016
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialisation of Pracinostat for the Treatment of Acute Myeloid Leukaemia and Other Haematologic DiseasesGet in Touch
For further information, please contact us using the form below.
Someone from the team will be in contact in due course.
Thank you for your form submission, we will get in contact with you shortly.